Defining the Healthy Phase I Study Participant

In Phase I research, healthy is not a fixed definition—it depends on the investigational drug’s mechanism, target organs, and risk profile. A volunteer may be suitable for one compound but not for another. Clinical assessment takes precedence over numerical cut‑offs, and some findings (e.g., sinus bradycardia in athletes or Gilbert’s syndrome) may still be compatible with trial inclusion.

Healthy volunteers help minimise confounding factors such as concomitant illness or interacting medications, allowing researchers to assess safety, tolerability, pharmacokinetics, and pharmacodynamics with greater clarity. However, exposing healthy people to risk requires stringent safety oversight, conservative stopping rules, and continuous monitoring.

Screening is multi‑layered and includes detailed medical history, physical exam, lab tests (haematology, chemistry, urinalysis), ECG, and vital signs. Importantly, clinicians must distinguish between clinically meaningful findings and benign variation—for example, mildly elevated ALT due to recent exercise versus pathological liver injury.

A participant’s health status is dynamic. Even placebo recipients can show changes (e.g., transient liver enzyme elevations or benign arrhythmias) due to confinement or study conditions. Therefore, participants are monitored against their own baseline, not just population norms. This approach improves detection of clinically meaningful changes and supports safer dose escalation decisions.

Yes—if supported by adequate nonclinical reproductive safety data. Their inclusion requires stringent risk‑mitigation measures, including sensitive pregnancy testing and use of highly effective contraception (<1% failure rate). Additional precautions are required when drugs may reduce hormonal contraceptive effectiveness (e.g., via enzyme induction).